$ACTU

ACTUATE THERAPEUTICS, INC.

Actuate Therapeutics is a clinical-stage biopharmaceutical company based in Fort Worth, Texas, developing therapies for difficult-to-treat cancers. Its lead drug candidate, elraglusib, is a small molecule designed to enter cancer cells and block the enzyme glycogen synthase kinase-3 beta. Actuate has exclusively licensed elraglusib, which was developed through a collaboration between the University of Illinois-Chicago and Northwestern University. Actuate is developing Elraglusib Injection for first-line treatment of metastatic pancreatic ductal adenocarcinoma and has evaluated it in pediatric patients with recurrent or refractory solid cancers. It has also selected an Elraglusib Oral Tablet for further development. The company collaborates with investigators on trials, providing the drug and input into study design.

4
0
1
$50K
—
SCHMITT DANIEL M
0%
See all $ACTU insider activity →
Med

Actuate reports preclinical data on oral elraglusib in melanoma

Actuate Therapeutics (ACTU) reported preclinical data showing its oral drug candidate elraglusib achieved up to 77% tumor growth inhibition in a melanoma model. The company plans to initiate a Phase 1/2 clinical trial in Q1 2027, starting with refractory metastatic melanoma patients. Elraglusib has previously shown promise in a Phase 2 trial for metastatic pancreatic cancer.

Actuate Advances Oral Elraglusib Toward 2027 Trial Following Positive Melanoma Data

Actuate Therapeutics (ACTU) reported positive preclinical data for its oral elraglusib tablet, showing tumor growth inhibition and immune-modulating effects in a melanoma mouse model. The company plans to present the findings at the EORTC-NCI-AACR Symposium in November 2026 and initiate a Phase 1/2 clinical trial in Q1 2027. The U.S. Patent Office issued a Notice of Allowance for the oral formulation's patent.

ACTU sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning ACTU (ACTUATE THERAPEUTICS, INC.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 1 bearish.

Recent ACTU coverage spans corporate actions, technology and financial news.

In the last 30 days, ACTU insiders filed 1 SEC Form 4 transaction — 1 purchase ($50K) and no sales. The most active reporter was SCHMITT DANIEL M, President, CEO and Director, with 1 filing.

What's driving ACTU

AlphAI scores every news story that mentions ACTU with an AI model for sentiment and relevance, and aggregates insider trades from ACTUATE THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ACTU

Score

Actuate reports preclinical data on oral elraglusib in melanoma

Actuate Therapeutics (ACTU) reported preclinical data showing its oral drug candidate elraglusib achieved up to 77% tumor growth inhibition in a melanoma model. The company plans to initiate a Phase 1/2 clinical trial in Q1 2027, starting with refractory metastatic melanoma patients. Elraglusib has previously shown promise in a Phase 2 trial for metastatic pancreatic cancer.

$ACTUMedAI 8/10

Actuate Advances Oral Elraglusib Toward 2027 Trial Following Positive Melanoma Data

Actuate Therapeutics (ACTU) reported positive preclinical data for its oral elraglusib tablet, showing tumor growth inhibition and immune-modulating effects in a melanoma mouse model. The company plans to present the findings at the EORTC-NCI-AACR Symposium in November 2026 and initiate a Phase 1/2 clinical trial in Q1 2027. The U.S. Patent Office issued a Notice of Allowance for the oral formulation's patent.

$ACTUMedOffering· $11M · priced

ACTUATE THERAPEUTICS, INC. (ACTU): Entry into a Material Definitive Agreement

ACTUATE THERAPEUTICS, INC. (ACTU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering CHICAGO, IL and FORT WORTH, TX, October 27, 2026 — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on devel

Actuate Therapeutics Reports Promising Initial Clinical Responses in Pediatric Cancers from Phase 1 Trial of Elraglusib

Actuate Therapeutics, Inc. announced promising initial clinical responses in pediatric cancers from its Phase 1 trial of elraglusib, noting two Complete Metabolic Responses in Ewing sarcoma and one Complete Response in neuroblastoma among 40 patients. The company plans to advance elraglusib's clinical development in 2026, especially for Ewing sarcoma, following its Rare Pediatric Designations from the FDA. Clinical responses and disease control were observed in 15 patients, with particular efficacy when elraglusib was combined with cyclophosphamide and topotecan.

Related tickers